Times of India
Stanford’s 20-year blood-cancer therapy treats first commercial patient; trial found 78% free of GVHD
In a remarkable advancement, Stanford researchers have unveiled Orca-T therapy, which has recently received FDA approval. After two decades of rigorous development, this innovative treatment was administered to its inaugural commercial patient, a high-risk leukemia sufferer. Nota